

## **Bod and the Lambert Initiative receive Australian Federal Government Innovation Connections Grant for collaboration**

- Bod enters research collaboration with the Lambert Initiative for the development of a compound marker required in the Phase I Clinical trial of Bod's sublingual cannabis wafer
- The Lambert Initiative was formed in 2015 following a \$33.7m donation from the Lambert family to the University of Sydney for research into therapeutic uses of medicinal cannabis
- The Innovations Connections Grant is awarded by the Department of Innovation, Industry and Science to assist in solving problems requiring access to leading researchers in a particular field - in this case, medicinal cannabis research
- The grant provides Bod with non-dilutive capital funding and will contribute approximately 50% of the total projects cost
- Phase I Clinical trial continues to progress - results expected November 2018, with success providing Bod with considerable upside potential

**Sydney, Australia – 25 September 2018:** Developer and distributor of natural, evidence-based cosmetics, natural medicines including medicinal cannabis and health products, Bod Australia Limited ("Bod" or the "Company") (ASX: BDA) is pleased to advise it has received a grant from the Australian Federal government for a research collaboration project with researchers from the University of Sydney's Lambert Initiative.

The Lambert initiative was established following a \$33.7 million donation from Barry and Jen Lambert, to the University of Sydney as part of the University's Brain and Mind Centre, to conduct high quality research to discover, develop and optimise safe and effective use of cannabinoid therapeutics in medicine.

The Lambert initiative is an Australian first in the field of medicinal cannabinoids, both in its breadth and depth of research innovation in advancing cannabinoid-based treatments in mainstream medicine to target paediatric, epilepsy, cancer, chronic pain, obesity, neurological and mental health disorders.

Under the collaboration, Bod and Lambert Initiative personnel will collaborate to develop the methods and materials required to analyse certain markers of cannabinoid metabolism. These compound markers can then be analysed in Bod's clinical trial program to delineate if the cannabinoid compound in its proprietary sublingual cannabis wafer product is being metabolised into one of the markers, possibly having an effect on the trial patients.

The development and publication of the methods for analysing these markers will provide a useful resource that can then be used for future studies that require assessment of cannabinoid metabolism.

These activities will be partly funded from the Innovations Connections Grant received from the Australian Federal Government. The Innovations Connections Grant, which is awarded by the Department of Innovation, Industry and Science, is focused on assisting businesses in solving problems that require access to leading research in a particular field, which in this case is medicinal cannabis research.

The Grant is designed to encourage and assist businesses to access knowledge, and engage with researchers to foster innovation. It will cover approximately 50% of the project cost and provides non-dilutive capital funding to Bod Australia.

**Associate Director, University of Sydney, Lambert Initiative, Dr Michael Bowen said:** “There is extremely limited publicly available information on how to properly analyse these particular markers of cannabinoid metabolism. We are hopeful that through this grant we will be able to develop and disseminate new knowledge that will assist in the development of innovative cannabinoid therapeutics”

**Bod Australia CEO Jo Patterson said:** “This collaboration with the Lambert Initiative, a leading authority in cannabinoid therapeutics, provides Bod with access to some of the nation's leading experts, affiliates and esteemed researchers in the field of medicinal cannabis and we are delighted to be working with them.

“Further, we are pleased that the quality of the partnership has attracted the attention and funding from the Government’s Department of Innovation, Industry and Science through the innovation connections grant.

“We look forward to progressing the development of a compound marker for use in our Phase I Clinical trial and providing shareholders with additional updates as the trial progresses.”

For more information: [bodaustralia.com](http://bodaustralia.com)

- ENDS -

## **About Bod Australia**

Bod Australia Limited operates two integrated business units. The Company is a developer and distributor of cosmetics, natural medicines and health supplements, focused on all natural, evidence based products. Bod has developed a significant distribution footprint in the Australian market with access to over 900 pharmacies and is also targeting Asian markets through key daigou relationships. Bod Australia has also build a multi-faceted cannabis business underpinned by a supply and collaboration agreement with Swiss botanical extracts manufacturer, Linnea Natural Pharma Solutions and an exclusive licence and manufacturing agreement with Singapore listed company iX Biopharma. The Company aims to develop a range of over the counter and therapeutic products based on GMP-certified cannabis extracts.

## **For more information please contact:**

Jo Patterson  
Bod Australia  
+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations  
[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au)  
+61 431 271 538